Analysts have been eager to weigh in on the Healthcare sector with new ratings on Edwards Lifesciences (EW) and Amgen (AMGN).
Edwards Lifesciences (EW)
Raymond James analyst Jayson Bedford maintained a Buy rating on Edwards Lifesciences today and set a price target of $96.00. The company’s shares closed last Thursday at $83.38.
According to TipRanks.com, Bedford is a 5-star analyst with an average return of 16.1% and a 71.8% success rate. Bedford covers the Healthcare sector, focusing on stocks such as Cardiovascular Systems, Merit Medical Systems, and Integra Lifesciences.
Edwards Lifesciences has an analyst consensus of Moderate Buy, with a price target consensus of $97.50, which is a 18.8% upside from current levels. In a report released yesterday, Oppenheimer also assigned a Buy rating to the stock with a $97.00 price target.
See today’s analyst top recommended stocks >>
Amgen (AMGN)
In a report released today, Dane Leone from Raymond James initiated coverage with a Hold rating on Amgen. The company’s shares closed last Thursday at $247.75.
According to TipRanks.com, Leone is a 5-star analyst with an average return of 17.1% and a 66.3% success rate. Leone covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Adverum Biotechnologies, and Tarsus Pharmaceuticals.
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $268.44, implying a 6.3% upside from current levels. In a report released today, Mizuho Securities also assigned a Hold rating to the stock with a $200.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.